New CIDP drug shows promise in early trial

NCT ID NCT04658472

Completed Disease control Sponsor: Bioverativ, a Sanofi company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a drug called SAR445088 in 98 adults with CIDP, a nerve disorder causing weakness and numbness. The trial looked at how well the drug works in people who are on standard treatment, those who don't respond to it, and those who haven't tried it yet. Researchers measured improvements in disability scores and monitored safety over 24 weeks, with a longer safety follow-up for some participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR445088 (a drug given intravenously or under the skin)
What this could lead to: If successful, this could point toward a new treatment option for people with CIDP, especially those who don't respond to current therapies.
What could go wrong: This is an early-phase, proof-of-concept study with a small number of participants. The drug may not prove effective or safe in larger trials, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY

Contacts and locations

Locations

Columbia University Site Number : 8400005

New York, New York, 10032, United States
Investigational Site Number : 1240001

Gatineau, Quebec, J8Y 1W2, Canada
Investigational Site Number : 1240002

Québec, G1J 1Z4, Canada
Investigational Site Number : 1560001

Shanghai, 200040, China
Investigational Site Number : 1560002

Fuzhou, 350001, China
Investigational Site Number : 1560004

Wuhan, 430030, China
Investigational Site Number : 2500001

Marseille, 13385, France
Investigational Site Number : 2500002

Nice, 06002, France
Investigational Site Number : 2500003

Bordeaux, France
Investigational Site Number : 2500004

Garches, 92380, France
Investigational Site Number : 2500005

Le Kremlin-Bicêtre, 94275, France
Investigational Site Number : 2760001

Düsseldorf, 40225, Germany
Investigational Site Number : 2760002

Göttingen, 37075, Germany
Investigational Site Number : 2760003

Essen, 45147, Germany
Investigational Site Number : 2760004

Tübingen, 72076, Germany
Investigational Site Number : 3800001

Milan, 20132, Italy
Investigational Site Number : 3800002

Rome, Lazio, 00168, Italy
Investigational Site Number : 3800003

Genova, 16132, Italy
Investigational Site Number : 3800005

Rozzano, Milano, 20089, Italy
Investigational Site Number : 5280001

Amsterdam, 1105AZ, Netherlands
Investigational Site Number : 5280002

Utrecht, 3584 CX, Netherlands
Investigational Site Number : 6160001

Lublin, Lublin Voivodeship, 20-954, Poland
Investigational Site Number : 6880001

Belgrade, 11000, Serbia
Investigational Site Number : 6880002

Belgrade, 11000, Serbia
Investigational Site Number : 6880003

Niš, 18000, Serbia
Investigational Site Number : 7240001

Barcelona, Barcelona [Barcelona], 08041, Spain
Investigational Site Number : 7240002

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7240003

Valencia, 46026, Spain
The University of Kansas Clinical Research Center Site Number : 8400003

Fairway, Kansas, 66205, United States
University of California Irvine Site Number : 8400002

Orange, California, 92868, United States
University of Minnesota Site Number : 8400006

Minneapolis, Minnesota, 55414, United States
University of Southern California Site Number : 8400004

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.